Talcum Powder Cancer Lawsuit

J & J Shareholders Call For Racial Audit Of The Company And An End To Talcum Powder Sales

Johnson & Johnson's Undoing May Be Having Racially Targeted Women Of Color With Talc Advertising They Knew Would Cause Cancer

Wednesday, April 27, 2022 - When all is said and done it is the shareholders who make the final decision for a publicly-traded company and Johnson & Johnson is no exception. The shareholders are the company's true owners as each share has one vote. Some people with large stakes in the company know that their voting rights are one of the two or three most important benefits of owning a company's common stock along with the potential for capital appreciation and dividend income. Today, Johnson & Johnson stockholders are prepared as a group to override the management of the company's board of directors and force the health care products and pharmaceuticals giant to discontinue selling Johnson's Baby Powder made from talc worldwide. The US Securities and Exchange Commission (SEC) has allowed the shareholder talc vote to proceed over objection from Johnson & Johnson's attorneys

When it comes to racial justice, "reprehensible conduct" does not start to describe how the company has put profits ahead of customer safety in the past five decades. According to The Guardian, the shareholders will also force a racial justice audit in light of the information the company has targeted women of color in countries like India and others, where the targeted market is darker-skinned women. The company is accused in talcum powder lawsuits by women of color in America suffering from ovarian cancer, and the estates of those who have died from the disease, of targeting them with their talcum powder advertising once they found out that its talc supply was contaminated with carcinogenic asbestos. "An internal Johnson & Johnson marketing report leaked in 2006 revealed it was specifically pushing the product to "curvy Southern women 18-49 skewing African American" and in underdeveloped geographical areas with hot weather, and higher [African American] populations," The Guardian reports. It has also come to light that Johnson & Johnson funded Nazi-like human experiments on black men who were in American prisons, injecting them with cancer-causing asbestos, and then with talc, ignoring the talcum powder cancer risks to compare the effects on their health from both. According to the Guardian, "Internal company memos show Johnson & Johnson for years marketed it to African American and overweight women and, the groups' charge, knew of the asbestos contamination. According to the Guardian, a letter was sent to the Vanguard investment group, the company's largest stockholder by proxy, insisting that the company discontinue all sales of talcum powder. "Johnson & Johnson has betrayed consumer and investor trust, while violating the rights of millions of individuals by selling asbestos-contaminated talcum baby powder, by intentionally targeting Black women in the marketing of this product, by refusing to admit wrongdoing, and by continuing to sell its talc-based baby powder worldwide," the letter reads." Johnson & Johnson discontinued selling their iconic talcum powder in North America when the US Food and Drug Administration (FDA) tested it and found it contained asbestos a known carcinogen. "The company recalled 33,000 bottles in October 2019 after the FDA detected chrysotile asbestos in a bottle purchased from an online retailer," according to The Guardian.

Information provided by TalcumPowderCancerLawsuit.com, a website devoted to providing news about talcum powder ovarian cancer lawsuits, as well as medical research and findings.

More Recent Talcum Powder Ovarian Cancer Lawsuit News:

View all Talcum Powder Cancer Lawsuit News

No-Cost, No-Obligation Baby Powder Lawsuit Case Review for Persons or Families of Persons Who Developed Ovarian Cancer After a History of Perineal Baby Powder Use

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.

Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.